How do you pay?
How many tablets?

How to pay the least

Cash price

$9,540+ for 30 tablets

Pharmacies pay about this for Kisqali; you’d pay more.

What to do

  1. Ask your pharmacy for Kisqali’s cash price, and one or two other pharmacies too.
  2. Kisqali’s savings card works only with insurance from a job or one you bought.

Other ways

Free from the maker, if you qualify Novartis Patient Assistance Foundation (NPAF). Patients must have a household income of less than or equal to $81,760 (for a household size of two) to be considered for NPAF. Or call 1-800-277-2254.

See if you qualify 

No generic is sold yet.

Compare every option

Brand name

Kisqali, the original

At least$9,540for 30 tablets; pharmacies pay this
Ways to save on Kisqali

The maker’s card

KISQALI Co-Pay Plus

Savings card from Novartis

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on us.kisqali.com 

Or call 1-866-433-8000.

In the maker’s words

“Eligible patients with private insurance may pay as little as $0…”

From the maker’s offer on us.kisqali.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized generic

There isn’t one.

Not soldThere isn’t one

Regular generic

No generic is sold yet.

Not soldNone sold yet

What it’s used for

What the FDA label says

KISQALI is a kinase inhibitor indicated:

  • in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.
  • for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with:
    • an aromatase inhibitor as initial endocrine-based therapy; or
    • fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy.

Source: the FDA label for Kisqali (Novartis Pharmaceuticals Corporation), July 1, 2026. Full label on DailyMed 

Good to know

  • “Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
  • Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
  • Don’t stop or change a medicine without talking to your pharmacist or prescriber.